logo
Will Silver Ever Break to the Upside?

Will Silver Ever Break to the Upside?

Globe and Mail2 days ago

I asked if silver was back on a bullish path in an April 17, 2025, Barchart article. I concluded that:
It may only be a matter of time before a herd of buyers descends on the silver market as the technical trend remains bullish, the fundamental deficit supports higher prices, and silver has become historically inexpensive compared to gold. A move over $37.58 per ounce will confirm the bullish trend and could lead to a parabolic move.
Nearby COMEX silver futures were at $32.985 per ounce on April 16 and was higher in late May 2025. However, the trend remains bullish, and silver can potentially surprise on the upside over the coming months.
Silver's technical trend is bullish
Silver's long-term path of least resistance remains bullish in late May 2025.
The seven-year continuous monthly COMEX silver futures chart highlights that the precious metal has made higher lows and higher highs since finding a bottom at the March 2020 low of $11.64 per ounce. Silver's most recent high of $35.495 in March 2025 was the highest price since March 2012.
Silver's deficit means fundamentals agree with technicals
In its April annual silver survey, The Silver Institute forecast 2025 silver supplies at 1.0306 billion ounces, with total demand at 1.148.3 billion ounces. The 117.70 million ounce fundamental deficit was the fifth consecutive year where demand outstripped supplies.
Each year, investment and speculative demand are crucial for the path of least resistance of silver prices. Given the bullish technical trend, the fundamental data supports a continuation of higher highs for the silver price. Moreover, the next upside technical target is the early 2012 $37.58 peak, which could be a gateway to a challenge of the 2011 $49.82 high and the 1980 record peak of $50.32 per ounce. A move over the $37.58 level could unleash a herd of buyers in the silver market.
The silver-gold ratio has been a relative value indicator for centuries, first proclaimed by the Egyptian Pharoah Menes, who died in 3125 BC. Menes declared that two and a half parts of silver equal one part of gold.
The thirty-year chart of the price of the continuous COMEX gold futures contract divided by the continuous COMEX silver futures contract ({GCM25}/{SIN25}) shows that the silver-gold ratio has been as low as 31.662:1 in 2011 when silver traded to nearly $50 per ounce, and as high as 124.648:1 in 2020 when silver fell to the $11.64 per ounce bottom. While the ratio has been trending higher since the 2011 low, it remains historically high. The relative value metric tells us that silver is inexpensive compared to gold at current prices.
The gold market has received lots of press as the price has risen to record highs in 2024 and 2025, while silver prices remain substantially below the record peak. However, market participants seeking value in the precious metals could turn to silver over the coming weeks, months, and years, as gold prices have experienced a parabolic rally.
Buying on weakness has been optimal since 2020
The seven-year monthly silver chart highlights that every significant downside correction in silver, including the 2020 low that led to the $11.64 bottom, has been a golden buying opportunity. At the most recent $35.495 2025 high, silver had over tripled from the 2020 low.
The most recent example was the April 7 risk-off lows created by the Trump administration's April 2 ' Liberation Day ' announcement that rolled out unprecedented tariffs on trading partners to level the playing field.
The daily chart of July COMEX silver futures shows the spike to a $27.845 per ounce April 7 low, a golden opportunity for silver accumulation. The price moved over $6 higher sixteen days later on April 23, 2025. Buying silver on price weakness has been optimal over the past years.
SLV is the most liquid silver ETF product
The most direct route for a long risk or investment position in silver is the physical market for bars and coins. However, silver is a bulky commodity, inhibiting self-storage, and third-party storage involves insurance and vaulting expenses. Moreover, independent dealer's bid-offer spreads on physical silver tend to be far wider than in the COMEX futures or London wholesale silver market. While the futures provide a physical delivery mechanism, they involve margin, creating leverage.
The most liquid silver ETF product is the iShares Silver Trust (SLV), which invests its considerable assets in allocated and unallocated silver bullion. At $30.45 per share, SLV had over $14.75 billion in assets under management. SLV trades an average of over 14.75 million shares daily and charges a 0.50% management fee.
The most recent rally in silver futures for July delivery took the price 22.16% higher from $27.845 on April 7 to a high of $34.015 on April 25.
Over around the same period, SLV rose 15.24% from $26.57 to $30.62 per share. The reason for SLV's underperformance is that the silver ETF can miss highs or lows when the stock market is closed, as the volatile silver futures trade around the clock.
With silver over the $32 per ounce level, the critical upside target is the $37.58 technical resistance level. Silver's relative value versus gold, the fundamental deficit, and the path of least resistance of silver prices since the 2020 low all point to a break above the resistance and a challenge of the 2011 and 1980 highs. However, buying on price weakness will likely remain optimal in the volatile silver market.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

$750 Million Market Projected to Reach $3.35 Billion Globally in 2034 for Abbreviated New Drug Application Filed on Preservative-Free IV Ketamine: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
$750 Million Market Projected to Reach $3.35 Billion Globally in 2034 for Abbreviated New Drug Application Filed on Preservative-Free IV Ketamine: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

Globe and Mail

time34 minutes ago

  • Globe and Mail

$750 Million Market Projected to Reach $3.35 Billion Globally in 2034 for Abbreviated New Drug Application Filed on Preservative-Free IV Ketamine: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

$NRXP Has $7.8 Million in Financing for Clinic Acquisitions and Purchase of Kadima Neuropsychiatry Institute as Treatment Model and Leading Investigative Site for Suicidal Depression / PTSD Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain. Aiming to be the First FDA-Approved Medication to Treat Suicidal Depression Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC). Abbreviated New Drug Application Filed for Preservative-Free IV Ketamine. Current Ketamine Market Estimated at $750 Million and Projected to Reach $3.35 Billion Globally in 2034. $7.8 Million Debt Financing to Fuel NRXP HOPE Clinic Acquisitions with Universal Capital, LLC. Added to Previously Announced Term Sheet with a Strategic Investor, NRXP HOPE Funding of $10.3 Million is Planned in Near Term. Agreement to Purchase Kadima Neuropsychiatry Institute Expected to Serve as Clinical Model for Treatment Offerings Nationwide. Kadima is a Leading Investigative Site for CNS and Psychedelic Research, Having Served as the Lead Site in Nearly All Major Trials in This Space. Dr. David Feifel, Nationally Recognized Pioneer in Interventional Psychiatry to join as Chief Medical Innovation Officer. New Drug Application for Treatment of Suicidal Depression; Planned NDA for Accelerated Approval for Bipolar Depression in People at Risk of Akathisia. Patent Application Filed for NRX-100 Proprietary, Preservative Free Formulation of IV Ketamine. Patent expected to be Orange Book Listable. Waiver Exemption from Paying a $4.3 Million New Drug Application Fee Under Prescription Drug User Fee Act (PDUFA). Accepted Non-Binding Potential Terms to License and Distribute NRX-100 Drug Providing Over $300 Million in Milestones Plus Tiered Double-Digit Royalties. Application to Uplist to NASDAQ Global Market from NASDAQ Capital Market NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI. NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality. Intravenous ketamine is widely accepted as a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product; the only treatment currently approved by the FDA is electroconvulsive therapy (ECT). According to the CDC, 3.8 million Americans make a plan for suicide each year. This represents a $3-5 billion market at expected pricing. Based on the data in the trials referenced above, the Company's regulatory counsel encouraged the Company to file an NDA for suicidal depression for NRX-100. In a January 2025 report, respected investment analysis firm D. Boral Capital assigned NRXP a $31 Price Target. The full report may be viewed at this link: Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine On June 5th NRXP announced the transmission of its Abbreviated New Drug Application (ANDA) for electronic filing to the U.S. Food and Drug Administration (FDA) for NRX-100, its preservative-free IV ketamine formulation, for use in all existing approved indications such as anesthesia and pain management. NRXP anticipates filing a citizen's petition with the FDA to remove benzethonium chloride, a known neurotoxic and cytotoxic substance, from presentations of ketamine intended for intravenous use. NRXP believes that the preservative-free feature of NRX-100 will be deemed of benefit to patients because of the known toxicity of closely related benzalkonium chloride in current drug products. Preservatives were originally added to sterile injectable products in an era when a single vial of medication was used to treat multiple patients, a practice no longer allowed in US hospitals. NRXP has demonstrated that there is no need for such preservatives to maintain stability and sterility in ketamine presentations intended for single-patient use. Should the citizen's petition be granted, all formulations of ketamine sold in the US could face a regulatory requirement to be preservative free. $7.8 Million Debt Financing to Fuel NRXP HOPE Clinic Acquisitions On May 15th NRXP announced signing of a term sheet with Universal Capital, LLC to provide $7.8 million in acquisition capital to initiate subsidiary HOPE's planned national rollup of interventional psychiatry clinics, commencing with previously-announced acquisitions of Dura Medical, Kadima, and NeuroSpa. Together with proceeds of a previously announced strategic investment, this financing is anticipated to provide $10.3 million in acquisition capital. HOPE's three initial acquisitions represent best-in-class clinics that offer neuroplastic treatments including NRXP ketamine and transcranial magnetic stimulation (TMS) to treat patients with severe depression, PTSD, and related central nervous system conditions. Neuroplastic treatments represent a rapidly emerging class of interventions that cause the growth of new connections (synapses) between brain cells that have been shown in multiple clinical trials to relieve symptoms of depression and suicidality. The FDA has approved TMS devices for a number of indications and has approved a nasal form of ketamine for treatment resistant depression. HOPE's parent company, NRXP, is currently applying to the FDA for approval of intravenous preservative-free ketamine to treat suicidal depression. Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the NRXP HOPE Network of Interventional Psychiatry Clinics On May 13th NRXP announced signing of a definitive agreement to purchase the Kadima Neuropsychiatry Institute. Kadima is expected to serve as the clinical model for treatment offerings in NRXP HOPE-acquired clinics and is expected to continue its role as a leading investigative site for research into neuroplastic therapies including psychedelic medications, transcranial magnetic stimulation (TMS), and hyperbaric therapy. Kadima is one of California's flagship interventional psychiatry clinics and was among the first to bring ketamine treatment for central nervous system (CNS) disorders out of academic research settings and into clinical practice. The clinic offers a full range of treatments for suicidal depression, PTSD and other CNS disorders, including ketamine, Spravato, transcranial magnetic stimulation ("TMS") as well as medication management. Further, Kadima and David Feifel, MD PhD, Founder and Medical Director of Kadima, have served as leaders in clinical trial work on emerging therapies in CNS for top companies in the industry. Importantly, the clinic is profitable and is forecast to continue growth going forward. Dr. Feifel will join NRXP HOPE as its first Chief Medical Innovation Officer upon closing of the acquisition. Patent Application Filed for NRX-100 Proprietary, Preservative Free Formulation of IV Ketamine On May 5th NRXP announced the filing of a patent application for NRX-100, its preservative-free intravenous ketamine formulation for the treatment of suicidal depression. The application discloses pharmaceutical compositions, methods of treatment and methods of manufacture and currently includes twenty claims. While subject to the patent review process of the US Patent and Trademark Office, if granted, the patent would provide NRX-100 exclusivity into 2045. This patent filing builds on the NRXP recently initiated filing of an NDA for NRX-100 and its prior Fast Track Designation, with NRX-101, from the FDA. If granted, the patent will help protect the innovation behind this formulation as NRXP advances its commercialization strategy. "We are committed to delivering safer, more effective treatments for patients with suicidal depression," said Jonathan Javitt MD MPH, CEO of NRXP. "NRX-100 eliminates the need for benzethonium chloride, a compound with well-documented safety concerns, and reflects our belief that patients in crisis deserve therapies formulated with their long-term well-being in mind. With the recent FDA fee waiver now in place, we remain on track to complete our NDA submission this quarter — a critical step toward bringing this innovation to patients in need." FDA Award of Filing Fee Waiver for Upcoming NRX-100 (preservative free ketamine) New Drug Application to Treat Patients with Suicidal Depression On April 30th NRXP announced the grant of a filing fee waiver by the US Food and Drug Administration ("FDA") to exempt the Company from a $4.3 million fee to file its New Drug Application for NRX-100 (preservative-free ketamine). The waiver is granted at the discretion of the FDA to Small Business Entities and for drugs that are deemed to be necessary for Public Health. NRXP anticipates that this waiver enables the completion of its New Drug Application for NRX-100 with currently-available corporate resources. The NDA filing is anticipated by the end of the second quarter of this year (Q2 2025). Disclosure listed on the CorporateAds website Media Contact Company Name: NRx Pharmaceuticals, Inc. Contact Person: Matthew Duffy, Chief Business Officer Email: Send Email Phone: 484 254 6134 Address: 1201 Orange Street Suite 600 City: Miami State: Florida Country: United States Website:

Silver Storm Closes First Tranche of Brokered Life Financing for Gross Proceeds of $10,541,050, Including Investment by Eric Sprott
Silver Storm Closes First Tranche of Brokered Life Financing for Gross Proceeds of $10,541,050, Including Investment by Eric Sprott

Globe and Mail

time34 minutes ago

  • Globe and Mail

Silver Storm Closes First Tranche of Brokered Life Financing for Gross Proceeds of $10,541,050, Including Investment by Eric Sprott

Silver Storm Mining Ltd. (' Silver Storm ' or the " Company") (TSX.V: SVRS | FSE: SVR), is pleased to announce that it has closed the first tranche (the ' First Tranche ') of its previously announced best efforts brokered private placement for total gross proceeds of $10,541,050 (the ' Offering '), which includes the partial exercise of the agents' option. Under the Offering, the Company sold 81,085,000 units of the Company (each, a ' Unit ') at a price of $0.13 per Unit (the ' Offering Price '). Red Cloud Securities Inc. is acting as lead agent and bookrunner for the Offering and Ventum Financial Corp. is acting as co-agent (collectively, the ' Agents '). The Offering was originally announced on June 20, 2025, and subsequently updated on June 29, 2025, and June 30, 2025. The First Tranche included a $1,001,000 investment from current significant shareholder by Eric Sprott, through 2176423 Ontario Ltd., a corporation which is beneficially owned by him. Each Unit consists of one common share of the Company (each, a ' Unit Share ') and one common share purchase warrant (each a ' Warrant '). Each Warrant entitles the holder to purchase one common share (each, a ' Warrant Share ') at a price of $0.20 at any time on or before that date which is thirty-six (36) months from the date of issuance. The Units were issued to Canadian purchasers pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions (' NI 45-106 ') and in reliance on the Coordinated Blanker Order 45-935 – Exemptions From Certain Conditions of the Listed Issuer Financing Exemption (the ' Listed Issuer Financing Exemption '). The Unit Shares and Warrant Shares underlying the Units are not subject to any hold period under applicable Canadian securities legislation if sold to purchasers resident in Canada. The Units sold under the Offering to offshore and purchasers in the United States were sold in accordance with OSC Rule 72-503 - Distributions Outside Canada (' OSC Rule 72-503 '). The Units sold to purchasers in the United States will be made on a private placement basis pursuant to one or more exemptions from registration requirements of the United States Securities Act of 1933, as amended (the ' U.S. Securities Act '). The Company intends to use the net proceeds from the Offering for: (i) the procurement of mine processing flotation cells; (ii) to commence rehabilitation work of the La Parrilla processing facility including equipment purchase and refurbishment, labour and supplies; (iii) to order long lead items including deposits on mining equipment and ventilation fans; (iv) to fund ongoing operations for the next twelve months; and (v) for general corporate and working capital purposes, all as further detailed in the Amended and Restated Offering Document (as hereinafter defined). There is an amended and restated offering document relating to the Offering dated May 30, 2025 (the " Amended and Restated Offering Document") that can be accessed under the Company's profile at and on the Company's website at Prospective investors in the Offering should read the Amended and Restated Offering Document before making an investment decision. As consideration for their services in the First Tranche of the Offering, the Agents and Harbourfront Wealth Management LLC received an aggregate cash payment of $540,735 and 4,159,500 non-transferable common share purchase warrants (the ' Broker Warrants '). Each Broker Warrant is exercisable into one common share of the Company at the Offering Price for a period of thirty-six (36) months from the date of issuance. The Offering remains subject to the final approval of the TSX Venture Exchange (the ' TSXV '). The remaining Offering amount of up to $1,470,950 from the sale of up to 11,315,000 Units at the Offering Price has been allocated to subscribers and the Company is expecting to close the final tranche of the Offering within the coming days. Eric Sprott through 2176423 Ontario Ltd., a corporation which is beneficially owned by him, and which holds greater than 10% of the Company's common shares, subscribed for 7,700,000 Units in the First Tranche of the Offering for an aggregate purchase price of $1,001,000 (the ' Insider Participation '). The Insider Participation will be considered a 'related party transaction' within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (' MI 61-101 '). The Company expects to rely on exemptions from the formal valuation and minority shareholder approval requirements provided under MI 61-101 pursuant to section 5.5(a) and section 5.7(1)(a) of MI 61-101, on the basis that the Insider Participation does not exceed 25% of the fair market value of the Company's market capitalization. The Company did not file a material change report in respect of the Insider Participation at least 21 days before expected closing date of the Offering as the Insider Participation was not confirmed prior to the foregoing period. This news release does not constitute an offer to sell or a solicitation of an offer to buy securities in the United States, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the U.S. Securities Act, as amended or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. About Silver Storm Mining Ltd. Silver Storm Mining Ltd. holds advanced-stage silver projects located in Durango, Mexico. In 2023 Silver Storm acquired of 100% of the La Parrilla Silver Mine Complex, a prolific past producing operation comprised of a 2,000 tpd mill as well as five underground mines and an open pit that collectively produced 34.3 million silver-equivalent ounces between 2005 and 2019. The Company also holds a 100% interest in the San Diego Project, which is among the largest undeveloped silver assets in Mexico. For more information regarding the Company and its projects, please visit our website at Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release. Cautionary Note Regarding Forward Looking Statements: Certain statements in this news release are forward-looking and involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of the phrase 'forward-looking information' in the Canadian Securities Administrators' National Instrument 51-102 – Continuous Disclosure Obligations. Forward-looking statements are not comprised of historical facts. Forward-looking statements include estimates and statements that describe the Company's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as 'believes', 'anticipates', 'expects', 'estimates', 'may', 'could', 'would', 'will', or 'plan'. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, the Company provides no assurance that actual results will meet management's expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release includes, but is not limited to: the intended use of proceeds of the Offering, the closing conditions of the Offering, statements with respect to the closing of the second tranche of the offering, including the timing and terms thereof, final TSXV approval of the Offering, statements with respect to the Insider Participation, including reliance on the MI 61-101 exemptions, the Company's plans and expectations for La Parrilla, and the ability to eventually place the La Parrilla Complex back into production. In making the forward-looking statements included in this news release, the Company have applied several material assumptions, including that the Offering will close on the anticipated terms or at all or may not close on the terms and conditions currently anticipated by the Company; that the Company will use the net proceeds of the Offering as anticipated; that the Company will receive all necessary approvals in respect of the Offering; the Company´s financial condition and development plans do not change because of unforeseen events, and management's ability to execute its business strategy and no unexpected or adverse regulatory changes with respect to La Parrilla, the decision to potentially place La Parrilla into production, other production related decisions or to otherwise carry out mining and processing operations, being largely based on internal non-public Company data and reports from previous operations and not based on NI 43-101 compliant reserve estimates, preliminary economic assessments, pre-feasibility or feasibility studies, resulting in higher risks than would be the case if a feasibility study were completed and relied upon to make a production decision. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein. Such forward-looking information represents managements best judgment based on information currently available. No forward-looking statement can be guaranteed, and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

Carney and Trump are holding direct talks to drop tariffs: sources
Carney and Trump are holding direct talks to drop tariffs: sources

CBC

time43 minutes ago

  • CBC

Carney and Trump are holding direct talks to drop tariffs: sources

Prime Minister Mark Carney and U.S. President Donald Trump are having direct discussions to reach a trade deal and lift tariffs, according to sources with knowledge of their talks. The two leaders agreed even before Canadians went to the polls this spring that they would chart a new economic and security deal, but the Canada-U.S. relationship appeared to hit a snag earlier this week when Trump doubled tariffs on all steel and aluminum imports. The tariffs, now at 50 per cent, are a further blow to the Canadian industries that are the U.S.'s biggest supplier of the metals. In response, Carney only said "intensive discussions" were ongoing and that his government was readying reprisals if negotiations with the United States failed. Sources, who spoke to CBC News and Radio-Canada on the condition they not be named, now say the two have been talking on the phone about reaching a deal. WATCH | Canadian exports to U.S. are dropping: Canadian exports to U.S. fell more than 15% in April as Trump tariffs hit 25 minutes ago Duration 4:05 There have been no public readouts of the calls. Carney and Trump met publicly last month at the White House, but no direct communication between the leaders had been confirmed since then. Earlier this week, Radio-Canada reported that Ottawa is hoping to reach an agreement with the Trump administration before the G7 summit — just 10 days from now in Alberta. Earlier this week, Trump's envoy to Canada, Ambassador Pete Hoekstra, told a crowd in Toronto the deal "is being settled at the highest levels of the U.S. government with the involvement of the highest elected officials."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store